This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
The strategies for all women included no screening, endocervical deoxyribonucleic acid (DNA) probe screening, endocervical nucleic acid amplification test (NAAT) screening, and urine NAAT screening. The strategies for men included no screening, urine NAAT screening for only those with leukocyte esterase-positive urine, and urine NAAT screening for all. Several combinations of male and female screening strategies were also considered.
Location/setting
USA/community.
Methods

Analytical approach:
This economic evaluation was based on a decision analytic model with a hypothetical cohort of 2,000 men and 2,000 women. The model had a 10-year time horizon. The authors stated that the analysis was carried out from the perspective of the public health care payer.
Effectiveness data:
The clinical data came from a selection of known, relevant published and unpublished studies and primary data collection. For instance, the chlamydia prevalence data were derived from a sample of men and women, who entered the New England job training programme between February 2001 and February 2004 . This study also provided data on the average number of partners for men and women aged 16 to 24 years. The accuracy of screening was calculated, using a modified meta-analytic approach, from studies identified through a Medline search, the details of which were provided in an appendix. Some assumptions, based on both authors' opinions and other published reports, were also made. The key clinical endpoint was the prevalence of disease.
Monetary benefit and utility valuations:
Not relevant.
Measure of benefit:
The summary benefit measure was the number of prevented cases of pelvic inflammatory disease (PID) and its sequelae (infertility, ectopic pregnancy, and chronic pelvic pain) in women, and of epididymitis in men.
The synthesis of costs and benefits was appropriately carried out using an incremental analysis. The expected costs and benefits were presented. The issue of uncertainty was restricted to a deterministic analysis, but this considered all the relevant model inputs and was presented in detail. The authors pointed out that their results might not be generalisable beyond a job training setting. They discussed the results of other studies, with some conflicting findings in the costeffectiveness of screening men for chlamydia. This study was conducted to overcome some of the limitations of these previous analyses.
Concluding remarks:
The study was based on appropriate methodology and was accurately described. The authors' conclusions are likely to be valid.
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